Date of Award
Doctor of Philosophy (PhD)
Psychology and Behavioral Sciences
Tony R. Young
The present study assessed whether the atypical antipsychotic agents olanzapine, risperidone, and quetiapine are associated with significant weight gain among adults with intellectual disabilities after 6 months of drug treatment. The body weights of 79 participants were retrieved 6 months prior to the initiation of drug treatment, at the start of the atypical antipsychotic agent, and after 6 months of drug therapy. Each individual served as his or her own control by utilizing pretreatment baseline trends in weight change to calculate a dependent measure of adjusted posttreatment weight gain. Doing so allowed for a stringent determination of the liability for weight gain during drug treatment. Results indicated that olanzapine, risperidone, and quetiapine are each associated with significant weight gain after 6 months of drug treatment. Individuals with mild to moderate intellectual disabilities evidenced more significant weight gain within that time period than those with severe to profound impairments.
Transier, Sherri Lyn, "" (2010). Dissertation. 461.